Gland Pharma
- Advice
- Hold
Gland Pharma Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Gland Pharma
Start SIPGland Pharma Investment Rating
-
Master Rating:
-
Gland Pharma has an operating revenue of Rs. 3,942.60 Cr. on a trailing 12-month basis. An annual revenue growth of 29% is outstanding, Pre-tax margin of 37% is great, ROE of 16% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 75 which is a FAIR score but needs to improve its earnings, a RS Rating of 8 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 84 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|
Oper Rev Qtr Cr | 926 | 1,048 | 857 | 1,103 |
Operating Expenses Qtr Cr | 642 | 753 | 587 | 755 |
Operating Profit Qtr Cr | 284 | 295 | 270 | 348 |
Depreciation Qtr Cr | 38 | 37 | 35 | 31 |
Interest Qtr Cr | 3 | 2 | 1 | 2 |
Tax Qtr Cr | 78 | 83 | 79 | 95 |
Net Profit Qtr Cr | 228 | 240 | 229 | 286 |
Gland Pharma Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 6
- Bearish Moving Average
- ___
- 10
- 20 Day
- 1251.52
- 50 Day
- 1324.13
- 100 Day
- 1507.35
- 200 Day
- 1866.62
- 20 Day
- 1237.78
- 50 Day
- 1288.84
- 100 Day
- 1477.83
- 200 Day
- 1901.18
Gland Pharma Resistance and Support
Resistance | |
---|---|
First Resistance | 1282.77 |
Second Resistance | 1310.89 |
Third Resistance | 1329.77 |
RSI | 49.14 |
MFI | 61.51 |
MACD Single Line | -25.55 |
MACD | -14.15 |
Support | |
---|---|
First Resistance | 1235.77 |
Second Resistance | 1216.89 |
Third Resistance | 1188.77 |
Gland Pharma Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 791,841 | 39,457,437 | 49.83 |
Week | 805,009 | 18,338,110 | 22.78 |
1 Month | 628,207 | 17,275,706 | 27.5 |
6 Month | 619,596 | 25,279,511 | 40.8 |
Gland Pharma Result Highlights
Gland Pharma Synopsis
NSE-Medical-Generic Drugs
Gland Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 4400.71 Cr. and Equity Capital is Rs. 16.43 Cr. for the Year ended 31/03/2022. Gland Pharma Ltd. is a Public Limited Listed company incorporated on 20/03/1978 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1978PLC002276 and registration number is 002276.Market Cap | 20,715 |
Sales | 3,934 |
Shares in Float | 6.92 |
No of funds | 153 |
Yield |
Book Value | 2.89 |
U/D Vol ratio | 0.8 |
LTDebt / Equity | |
Alpha | -0.34 |
Beta | 0.48 |
Gland Pharma
Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
---|---|---|---|---|
Promoters | 57.86% | 57.86% | 57.87% | |
Mutual Funds | 19.49% | 18.48% | 15.54% | |
Insurance Companies | 2.59% | 2.1% | 1.17% | |
Foreign Portfolio Investors | 4.67% | 6.1% | 9.41% | |
Individual Investors | 4.02% | 3.78% | 3.71% | |
Others | 11.37% | 11.68% | 12.3% |
Gland Pharma Management
Name | Designation |
---|---|
Mr. Yiu Kwan Stanley Lau | Chairman & Ind.Director |
Mr. Srinivas Sadu | Managing Director & CEO |
Mr. Qiyu Chen | Non Executive Director |
Mr. Yifang Wu | Non Executive Director |
Mr. Yao Fang | Non Executive Director |
Ms. Xiaohui Guan | Non Executive Director |
Mr. Udo Johannes Vetter | Independent Director |
Dr. Jia Ai (Allen) Zhang | Non Executive Director |
Mr. Satyanarayana Murthy Chavali | Independent Director |
Mr. Essaji Goolam Vahanvati | Independent Director |
Ms. Naina Lal Kidwai | Independent Director |
Gland Pharma Forecast
Price Estimates
About Company
Gland Pharma FAQs
What is Share Price of Gland Pharma ?
Gland Pharma share price is ₹1257 As on 30 March, 2023 | 14:18
What is the Market Cap of Gland Pharma ?
The Market Cap of Gland Pharma is ₹20714.7 Cr As on 30 March, 2023 | 14:18
What is the P/E ratio of Gland Pharma ?
The P/E ratio of Gland Pharma is 21 As on 30 March, 2023 | 14:18
What is the PB ratio of Gland Pharma ?
The PB ratio of Gland Pharma is 2.9 As on 30 March, 2023 | 14:18
Is it a good time to invest in Gland Pharma Limited?
Gland Pharma has an operating revenue of Rs.3,981.54 Cr. on a trailing 12-month basis. An annual revenue growth of 30% is outstanding, Pre-tax margin of 39% is great. Various broking houses and analysts recommend 'BUY' on the stock.
What is the stock price CAGR of Gland Pharma Limited?
The stock price CAGR of Gland Pharma Limited for 1 Year is 66%.
Is Gland Pharma Limited debt-free?
Gland Pharma Limited is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.
What is the ROE of Gland Pharma Limited?
The ROE of Gland Pharma Limited is 16% is which good.
Who is the Managing Director of Gland Pharma Limited?
Mr. Srinivas Sadu is the Managing Director & Chief Executive Officer of Gland Pharma Limited.
How to buy shares of Gland Pharma Ltd online?
The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.
What are some of the competitors of Gland Pharma Ltd?
Given below is the list of companies that belong to the same industry or manufacture products of a similar niche as Gland Pharma Ltd.
- Cipla
- Sun Pharma
- Pfizer
- Lupin
- Eris Life
- Aarti Drugs
- Hester Bio
- RPG Life
- Bafna Pharma
- Jb Chemicals